We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The global police organization Interpol issued a warning yesterday to countries to prepare for a new wave of organized criminal activity, including cyber hacking of drugmakers as governments prepare to ship their vaccines. Read More
Wren has pioneered a new approach to protein misfolding diseases that uses a predictive method in place of the traditional drug discovery and biological approaches. Read More
AstraZeneca is selling off limited rights to its former blockbuster statin drug Crestor to Grünenthal for $320 million upfront and possible future milestone payments of up to $30 million. Read More
Novavax said it will begin a delayed phase 3 trial in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, “in the coming weeks” and that its 15,000-person late-stage trial in the UK is now fully enrolled. Read More
United Biomedical’s nonprofit vaccine subsidiary, Covaxx, said it has secured supply deals worth $2.8 billion for more than 140 million doses of its COVID-19 vaccine candidate, UB-612, in “multiple countries,” including Brazil, Ecuador and Peru. Read More
Merck is expanding further into the biotech sector by acquiring Rockville, Md., biopharma company OncoImmune for $425 million, netting in the process an investigational drug that has shown promise as a treatment for hospitalized COVID-19 patients. Read More
As some of the world’s largest drugmakers gear up to manufacture and distribute COVID-19 vaccines, a relatively tiny competitor, Massachusetts-based Moderna, faces some unique challenges. Read More
Previously, Lilly said it expects to manufacture up to 1 million doses of the 700-mg dose of bamlanivimab globally by the end of the year and anticipates supply to increase significantly in the first quarter of 2021. Read More